Comparative evaluation of isavuconazonium sulfate, voriconazole, and posaconazole for the management of invasive fungal infections in an academic medical center.

Edward T Van MatreShelby L EvansScott W MuellerRobert MacLarenDouglas N FishTyree Heath Kiser

Published in: Annals of clinical microbiology and antimicrobials (2019)

Patients treated with isavuconazole resulted in fewer composite safety outcomes, driven by decreased incidence of QTc prolongation, compared to patients treated with voriconazole or posaconazole. Overall drug cost was not significantly different between the treatment therapy options.

Keyphrases

risk factors
drug induced
type diabetes
stem cells
metabolic syndrome
adverse drug
weight loss